Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05009199 · ClinicalTrials.gov registry record · Phase 1
Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444
A Phase 1 study of Healthy Volunteer, sponsored by Invicro.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT05009199: Completed Phase 1 study of Healthy Volunteer, sponsored by Invicro.
NCT05009199 is a Phase 1 study of Healthy Volunteer that has completed, run by Invicro. The registered enrollment target is 3 participants, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05009199, a Phase 1 study of Healthy Volunteer, has completed, sponsored by Invicro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this protocol is to evaluate the binding of caffeine to adenosine A2A receptors in the brain of participants at risk for developing PD.
Primary Outcome
A2A receptor occupancy will be assessed by comparing the binding potential (BPND) of \[18F\]MNI-444 in striatal regions of interest (ROIs) for each post-dose scan (ie, peak and trough scans assessed separately) with the baseline scan in the same participant.
Conditions Studied
Interventions
- DRUG [18F]MNI-444
Study Locations (1)
Connecticut
- Invicro - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-06-24 |
| Est. Completion | 2022-05-12 |
| Phase | Phase 1 |
What the finished NCT05009199 record still lists
NCT05009199 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 1 intervention - of which [18F]MNI-444 is the first listed.
NCT05009199 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05009199 about?
NCT05009199 is a clinical study titled "Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444". The overall goal of this protocol is to evaluate the binding of caffeine to adenosine A2A receptors in the brain of participants at risk for developing PD.
What is the current status of trial NCT05009199?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-06-24. Estimated completion is 2022-05-12.
What conditions does trial NCT05009199 study?
This clinical trial studies the following conditions: Healthy Volunteer.
What interventions are being tested in trial NCT05009199?
The interventions under investigation include: [18F]MNI-444 (DRUG).
Who is sponsoring clinical trial NCT05009199?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05009199 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05009199's enrollment target sits among peer trials
3 113th of 112 the lowest of 112 other Healthy Volunteer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Volunteer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Healthy Volunteer Study
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors
RECRUITING · Phase 1
-
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
RECRUITING · Phase 1
-
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI